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 Human induced pluripotent stem cells offer a model for human brain development 
and disease by differentiation into brain organoids; however, current neural culture 
systems lack the microenvironment, neuronal circuits and connectivity, vascular 
circulation, and immune system that exist in vivo. After differentiation and development 
of neuronal and non-neuronal cell types within two formats of cell cultures, we can 
visualize and recapitulate in vivo protein accumulation, gene expression, and degradative 
processes such as autophagy. Using RNA extraction, purification methods and reverse 
transcription I compared traditional monolayer cultures and novel 3-D neural sphere 
cultures via gene expression analysis. This analysis indicated variable gene expression 
between formats therefore only monolayer cultures were analyzed for tau protein 
accumulation with pharmacologic treatments and measured by Western blot. I also report 
on cell type specific gene expression by transient transfection of plasmid cassette tools 
and fluorescent microscopy. Here, cell type specific gene targeting is demonstrated in 
successfully transfected cells. Further development of the tools utilized in this study will 




target specific cell types within mixed cultures, and allowing for a more accurate 
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Figure 25. EGFP expression in HEK293t cells based on reporter gene(s). All panels 
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cells express low levels of EGFP after transfected with SYN1-CRISPR cassette. EGFP 
expression assumed to be due to CRISPR integration, though the SYN1 promoter should 
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differentiated. Lane 3 shows 21 days differentiated. Lane 4 shows 28 days differentiated. 
(BOTTOM) Enlarged image of differentiation day 9 exhibits cells expressing EGFP with 
a morphology resembling astrocytes. ............................................................................... 56 
Figure 29. Neural cells after transfection with oligodendrocytic CNP-GFP plasmid 
cassette. Fluorescent microscopy reveals extremely low levels of EGFP expression in 
iPSC derived neural cells. (TOP) Cells transfected with plasmid cassettes containing 
EGFP sequences induced by CNP reporter promoter. After transfection, cells were 
subsequently differentiated by FGF withdrawal. Lane 1 shows cells at day 2 of 
differentiation. Lane 2 shows nine days differentiated. Lane 3 shows 18 days 
differentiated. (BOTTOM) Enlarged image of differentiation day 9 exhibits cells 




Figure 30. Neural cells after transfection with Neuronal SYN1-GFP plasmid cassette. 
Fluorescent microscopy reveals relatively low levels of EGFP expression in iPSC derived 
neural cells. Cells transfected with plasmid cassettes containing EGFP sequences induced 
by SYN1 reporter promoter. After transfection, cells were subsequently differentiated by 
FGF withdrawal. Lane 1 shows cells at day 2 of differentiation. Lane 2 shows 9 days 
differentiated. Lane 3 shows 18 days differentiated. Enlarged images (indicated by red 
lines) exhibit cells expressing EGFP after 18 days of differentiation. ............................. 59 
Figure 31. Neural cells after transfection with neuronal PRNP-GFP plasmid cassette. 
Fluorescent microscopy reveals relatively high levels of EGFP expression in iPSC 
derived neural cells. Cells transfected with plasmid cassettes containing EGFP sequences 
induced by SYN1 reporter promoter. After transfection, cells were subsequently 
differentiated by FGF withdrawal. (TOP) Lane 1 shows cells at day 2 of differentiation. 
Lane 2 shows 9 days differentiated. Lane 3 shows 28 days differentiated. Lane 4 shows 
34 days differentiated. (BOTTOM) Enlarged image exhibits cells expressing EGFP after 
34 days of differentiation. ................................................................................................. 61 
Figure 32. Neural cells after transfection with no plasmid cassette. Fluorescent 
microscopy reveals some EGFP expression in iPSC derived neural cells. After 
“transfection”, cells were subsequently differentiated by FGF withdrawal. Lane 1, cells at 
day 21 of differentiation. Lane 2, 25 days differentiated. Lane 3, 28 days differentiated. 62 
Figure 33. Bright field micrographs of 2D monolayer (left) and 3-D neural spheres 
(right). Cells displayed here were cultured from CV17q iPSC derived neural progenitor 
cells and further differentiated. (Left) Bright field microscopy shows the monolayer cell 
cultures, traditionally used in neural developmental research. (Right) Bright field 
microscopy showing different growth stages of differentiated neural spheres. Axons and 
dendrites can be more easily distinguished in the 3-D cultures as well as obvious 






 Microtubule associated protein tau (MAPT) has been implicated in a specific class 
of neurodegenerative diseases called tauopathies which leave millions devastated 
worldwide (Larsen et al. 2015). Tauopathies are characterized by specific isoforms of 
misfolded, insoluble, hyperphosphorylated tau protein which aggregate as neurofibrillary 
tangles in the brain (Iqbal et al. 2010). The MAPT gene encodes the tau protein where six 
different splice variants exist in the adult human brain. Criteria used for classification of 
these diseases include protein binding domains and/or number of N-terminal domains. 
Contingent upon exon 10, tau is first identified as 3 (3R) or 4 (4R) repeats by the number 
of microtubule binding domains. 3R is a "signpost" for tauopathies such as Myotonic 
dystrophy and Pick’s disease. 4R tau is indicative of several other tauopathies: 
corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and argyrophilic 
grain disease (AGD); sporadic predominant primary tauopathies that accumulate 
hyperphosphorylated tau within neurons, oligodendrocytes, and astrocytes. While 
different ratios also categorize these diseases (de Silva et al. 2006), differences between 
isoforms, as well as cell type (neurons vs. glia) in which aggregation occurs, may be 
attributed to the gene expression patterns and primary function of MAPT. Isoforms are 
classified further by 0, 1, or 2 N-terminal domains (Iqbal et al. 2010). A critical question 
in the study of tauopathies is how abnormal expression of MAPT is managed by neurons, 
astrocytes, and oligodendrocytes, and which pathways are required to maintain viability 






 The Ubiquitin proteasome system (UPS) and autophagy pathway use 
ubiquitylation as a signal to coordinate and localize (protein) cargo for degradation. The 
proteasome prevents the accumulation of misfolded proteins, influences the cell cycle, 
and regulates the immune response (Tai and Schumann 2008). The UPS has a size 
limitation for molecules that may be degraded. When this system becomes impaired or a 
substrate cannot fit, UPS inhibition induces autophagy as an auxiliary system which then 
non-selectively clears protein (Tang et al. 2014, Lotfy 2016, Bose and Cho 2017). Non-
native protein conformations are usually selectively recognized by chaperones and 
undergo repair or refolding. If chaperone repairing activity fails to execute, the altered 
proteins are processed to the UPS for degradation (Martini-Stoica et al. 2016). However, 
if the UPS functionality is impaired or if the protein has already generated insoluble 
structures, autophagy is the only option for complexed toxic protein removal (Bose and 
Cho 2017). Autophagy is a system that delivers cytoplasmic components, tagged by 
ubiquitin, to lysosomes for terminal degradation and dysfunction of this pathway is 
hypothesized to play a key role in the pathogenesis of several neurodegenerative diseases 
(Nedelsky et al. 2008). In the autophagy pathway, autophagosomes are formed by 
sequential functions of autophagy-related (ATG) proteins. Microtubule-associated protein 
light chain 3 (LC3) is required in the recruitment of substrates to the autophagosome 
(Martini-Stoica et al. 2016). The cytosolic form of LC3 known here as LC3-I, becomes 





modified-LC3 known as LC3-II. This LC3-II associates with the autophagosome 
membrane and then sequester its cargo within the autophagosome for degradation. 
Studies of upstream signaling pathways, autophagosome formation, and autophagosome 
maturation/fusion with lysosomes are critical in addressing which isoform(s) of tau are 
present in each cell, which isoform(s) are signaled for degradation and by which 
pathway, as well as understanding autophagy clearance and how tauopathies manifest in 
human brain cells. 
Modeling Tauopathies 
 Misfolded, insoluble tau proteins are characteristic of tauopathies and form the 
neurofibrillary tangles. Those who develop a neurodegenerative disease usually exhibit 
memory impairment associated with brain atrophy and neuronal loss due to presence of 
extracellular accumulation of plaques and neurofibrillary tangles in the brain.
 Differentiation of induced pluripotent stem cells (iPSCs) has allowed us to study 
the overall development of many cell types and tissue layers as well as the underlying 
molecular mechanisms that activate and manage the development/construction of these 
elements. After somatic cell-nuclear transfer, in which allocation of nuclear content into 
oocytes is established, or by embryonic stem cell fusion, cell cultures can be reverted to 
embryonic-like cells (Takahashi and Yamanaka 2006). With the addition of appropriate 
signaling factors, iPSCs can be coaxed to yield eye, gut, liver, kidney, and other human 
tissues. Similar to these 3D multicellular structures, aggregates of iPSCs specific to 





interdependent and discrete brain regions develop to contain progenitor zone organization 
of human cortical neuronal subtypes termed cerebral organoids (Lancaster et al. 2013). 
Conservation of signal transduction and cellular connections should be an empirical 
intention/objective with iPSCs.  
 We can now study fluctuation in anatomical brain networks by focusing on brain 
network development, network structure, and network function where spatial and 
temporal factors have been demonstrated to shape connectome development (Kaiser 
2017). Underlying molecular signals, spatial distance between cells and their 
environments, and the length of time when these signals are activated could influence 
neural development and synapse maturity (Cahoy et al. 2008). These factors also share 
importance in the influence of connections made between cells and the organization of 
signal pathways during brain development (Kaiser 2017). The visualization of tissue 
structures, based on gene expression, will provide us with contemporary measurements of 
spatial/temporal and functional development through cell signaling pathways. 
 Studies of MAPT knockout in mouse models have suggested that the MAPT gene 
has little to no effect on normal cell development and do not often recapitulate human 
disease especially in central nervous system models (van Hummel 2016). Mansour et al. 
(2018) hypothesized that intracerebral implantation of human stem cell derived brain 
organoids in mice could create an accommodating environment for organoid 
development and long-term survival. After transplantation into adult mouse brains, 
vascularization and connectome was established. Based on lentiviral transduction and 





gliogenesis, and microglia integration. Transgenic mouse models can recapitulate disease 
phenotypes, however there are concerns about the validity of these models; a number of 
genetic variants of human diseases are located in non-coding regions that are not 
conserved between species. With the advent of iPSC technology, pluripotent cell types 
have been used as an alternative way to model tauopathies (Raja et al. 2016). Transgenic 
studies could still provide insight into novel treatments for brain disorders or injuries 
however, since mouse and human models differ, the current experiment was performed 
solely on human cell lines for a more precise explication of human neural 
characterization.  
 Here I validate the CV17q cell line as a tauopathy model and CV4a line as a 
control. I used and discuss the derivation and differentiation of healthy and diseased iPSC 
lines in two formats. Induced pluripotent stem cells have been derived from a human 
donor with a fully published and sequenced genome (Israel et al. 2012). Craig Venter’s 
diploid genome has been sequenced in high resolution and made publicly available, and 
because he has not developed a neurodegenerative disease (at present time), CV4a 
clonally selected and differentiated neural progenitor cells were used as a healthy control. 
Based on single nucleotide polymorphism (SNP) array data from Jordan Dizon’s 
Master’s Thesis (2016), CV17 amplification (CV17q) cell line (derived from CV4a) 
contains a spontaneously amplified ~40Mbp sequence from the 17q chromosome to 
provide a 3rd copy of the MAPT gene. This amplification also includes several other 
genes which may be supplementary but irrelevant to this study. It is the consideration of 





model of tauopathy, though no pathology of any disease has yet been investigated. 
 The following specific aims address the central hypothesis. There is a gap in 
knowledge about the mechanisms of neural development, and the intricate roles of cell 
signaling, gene expression, and tau protein accumulation within diseased vs healthy cell 
types. MAPT gene products are implicated in the accumulation of toxic tau species in 
vulnerable cell types. The long-term goal of this project was early and targeted activation 
of the autophagy pathway to develop effective reiteration of in vivo processes using in 
vitro methodologies to promote specific clearance of pathogenic tau species. The 
identification and further analysis of fundamental gene expression and cell signaling is 
essential in exposing new diagnostic and discovery tools for the intervention/prevention 
of these diseases regarding the following central hypothesis that disruption of autophagy-
essential protein components will produce disease-like cellular phenotypes and 
accelerated cell death in populations of human neural cultures. The overall objective was 
to determine the role of autophagy in the turnover of misfolded tau protein by human 
neural cells. Gene expression profiles in adherent vs 3-D neural sphere iPSC derived cell 
lines were also determined in support of the rationale that development of novel 
treatment strategies for intervention and/or prevention will alter the course of more than 






1. Evaluation of gene expression in 3-D neural sphere vs standard, adherent cell cultures. 
 Stable and viable cells that have the potential of disease inheritance can be 
developed and scrutinized through neural progenitor differentiation using induced 
pluripotent stem cells with a cell line with a fully sequenced and published genome 
(Israel et al. 2012). Our iPSC lines were clonally selected and differentiated into neural 
progenitor cells from which brain cells can be further differentiated. Culture samples 
were developed in vitro by differentiating iPSCs into neurons, astrocytes, and 
oligodendrocytes which make up neural tissue of the CNS. Typically, cells are adhered to 
a surface and differentiated where restricted spatial factors establish connectome 
expansion. Compared with 2D sheets of neural cells, 3-D structures have an extended 
lifespan and can consist of heterogeneous populations. They also mimic key features of 
developing brains (Farahany et al. 2018). Primer sets target and amplify selected gene 
sequences where I hypothesized that expression of these genetic comparisons between 
adherent lines and 3-D non-adherent (neural sphere) lines would validate 3-D neural 
spheres as more accurate representations of in vivo physiological connectome and 
development. 
2. Establishing cell-specific plasmid tools to target neurons, astrocytes, or 
oligodendrocytes within mixed cultures and label them with EGFP.  
 To ascertain information about the development of brain cells, populations of 





protein (EGFP) induced by cell type specific reporter gene promoters (Figure 1) to 
visualize cells of interest. The detection of antibodies through fluorescent microscopy 
confirms cell type specific gene expression. Fluorescent images generate a map from 
which patterns of gene expression can further be organized. It was expected that these 
plasmid cassette tools would permit highly reproducible results in which different cell 
lines and their cell type specific gene expression may be evaluated. 
 
Figure 1. Illustration of the AAVS1 donor plasmid including left and right homology arms, splice acceptor 
(SA), thiophene-2-acetate (T2A) cleavable linker, puromycin (Puro R) resistance. Post digestion with Sal I 
and inclusion of cell specific promoters allow EGFP expression in cell types of interest. Further digestion 
with ECORV and inclusion of CRISPR constructs to be activated via promoter within specific cell types. 
EEF1A1, GFAP, CNP, SYN1, OR PRNP were integrated into exclusive plasmid cassettes. 
 
3. To determine the role of autophagosomes in the clearance and turnover of tau in brain 
cells.  
 Native tau is normally degraded by the UPS and if tau becomes misfolded, 
mechanisms are implemented to refold or degrade the protein. Misfolded tau protein is 
degraded primarily by the autophagy pathway and alternatively degraded via ubiquitin 
proteasome (Tang et al. 2014, Ciechanover and Kwon 2015, Bose and Cho 2017). 
 The proposed drug panel (Table 1) and molecular protein targeting implemented 





degradation based on the levels of individual tau isoforms, total tau, and LC3 protein(s). 
Activation of one or both degradative pathways stimulates the degradation of tau protein 
whereas inhibition of the same pathway(s) results in accumulation of protein and may be 
associated with the viability of each cell type. It has been established that drug regulation 
of LC3-II may elucidate autophagosome and ubiquitin binding inhibition, as well as other 
pathway mechanisms to investigate tau specific degradation.  
Table 1. Pharmacologic pathway modulators. Compounds used to treat cell lines with known function 
related to cellular pathways and processes. 
  
Compound Effect on Cellular Pathway(s) 
Rapamycin mTOR Inhibitor-Autophagy Activator 
Torin1 mTORC1/2 Inhibitor-Autophagy Activator 
SCD1 Autophagy Inhibitor (inhibits 
autophagosome formation) 
Spautin1 Autophagy Inhibitor (inhibits 
autophagosome formation) 
Bafilomycin A1 (BafA1) vATPase Inhibitor 
Chloroquine (CQ) Inhibitor Lysosomal Acidification 
MG-132 UPS Inhibitor 
Simvastatin HMG-CoA Reductase Inhibitor 
(Cholesterol) 
Nystatin Lipid Raft Inhibitor (Ionophore) 
FCCP Mitochondrial Oxidative Phosphorylation 
Uncoupler  
PuAD HSP90 Inhibitor 





MATERIALS AND METHODS 
Cell Culture 
 Induced pluripotent stem cell lines were obtained from the Goldstein laboratory at 
University of California San Diego’s Sanford Consortium for Regenerative Medicine. 
Primary fibroblasts were previously extracted from patients via dermal punch biopsy and 
re-programmed to an embryonic-like state by transduction of supplemental signaling 
factors (Takahashi and Yamanaka 2006, Okita et al. 2007). Fibroblasts were transduced 
with vectors containing complementary DNA for OCT4, SOX2, KLF4, c-MYC and 
EGFP, and initiated cell fate lineages of ectodermal, mesodermal and endodermal cell 
types (Israel et al. 2012). Once pluripotency had been established, iPSC lines were 
differentiated into neural progenitor cultures (NPCs) containing neural rosettes (Wilson 
and Stice 2006, Israel et al. 2012) and then purified, as detailed below. Derived NPCs 
were differentiated for 3 weeks. Neural cells sequentially collected and purified by 
fluorescence activated cell sorting were assessed to be >90% neurons, based on present 
βIII-tubulin1, and MAP2 projections. 
Adherent cells 
 Originating from J. Craig Venter, CV4a and CV17q iPSC cell lines had been 
derived through iPSC differentiation (Takahashi and Yamanaka 2006, Wilson and Stice 
2006, Okita et al. 2007, Israel et al. 2012). These iPSC lines had been previously clonally 
selected with antigen markers and then differentiated into neural progenitor cells from 





 Neural progenitor cells were thawed from freezing media (NPCb + 10% DMSO), 
washed with Hank's Balanced Salt Solution, and plated on PLO/Laminin (Sigma-Aldrich, 
Poly-L-Ornithine hydrobromide)/(Corning, Mouse Laminin Ref. 354232) coated plates 
(Fisher brand, Polystyrene tissue culture treated low evaporation lid, flat bottom plates 
Ref. FB012927) in NPCb cell media (DMEM/F12 + GlutaMAX (Gibco; Ref. 10565-
018), 1%  Pen-Strep antibiotics (Gibco; Ref. 15140-122) 0.5x B-27 supplement (Gibco, 
Ref.17504-044), 0.5x N-2 supplement (Gibco; Ref. 17502-048), and 20ng/ml Fibroblast 
Growth Factor (FGF PeproTech Animal-Free Recombinant Human FGF-basic, Ref. 
AF10018B100UG). Cells were grown to confluency and acutase (lot# 752919A) was 
used to dissociate the cells. Cells were counted on a hemocytometer and plated at 
>100,000 cells/ml. Passaged cells were re-adhered and differentiated from NPCs in 
NPCb following FGF withdrawal by media change. Media was changed once each week. 
3-D neural spheres 
 Adhered NPCs were dissociated into single cell suspension using acutase. Cells 
were counted on a hemocytometer and resuspended in NPCb at >100,000 cells/ml. NPCs 
were transferred to non-coated plates, suspended in media containing 2ul/ml FGF, and 
shaken at 90RPMs on an orbital shaker. Cells were differentiated from NPCs in NPCb 
following FGF withdrawal by media change. 
Differentiation and collection of NPCs/NSCs 
 2-D monolayer and 3D neural sphere cultures developed from NPCs in NPCb + 
FGF were replated and after successive FGF withdrawal, samples were collected every 4 





Maintenance of cell cultures for drug treatments and protein analysis 
 NPCs were adhered to plates and grown to confluency as described previously. 
Cells were differentiated for 28 days via FGF withdrawal. Cells were dissociated and 
replated at a density of ~50,000 cells/well onto 96-well plates. Cells were counted using 
trypan blue to help determine cell viability. 
Cell collection for Western blots and subsequent protein analysis 
 Based on cell viability assays, concentrations B and D (Table 2) were selected for 
protein analysis via Western blot. Cells were washed in PBS and lysed in buffer 
containing EDTA-Free Protease and Phosphatase inhibitors (Pierce, Mini Tablets 88669). 
Lysate protein concentrations were diluted to a maximum of 20ug/50ul. Samples with 
lower concentrations were collected in 40ul lysis buffer and 10ul 5x loading dye. 
Reactions were boiled at 100°C for 10 minutes in a thermocycler.   
Table 2. Stock concentrations were initially diluted in NPCb and further diluted at 50ul treatments into 
100ul NPCb. Table displays stock and diluted concentrations of each drug treatment. Color coded for drug 
concentration. 
 








Rapamycin 2.74mM 5.48uM 1.83uM 0.61uM 0.20uM 
Torin 1mM 2.04uM 0.68uM 0.23uM 0.08uM 
SCD1 10mM 20.8uM 7.0uM 2.36uM 0.79uM 
Spautin1 20mM 42.4uM 14.3uM 4.85uM 1.64uM 
Baf A1 100uM 216nM 73.44nM 24.97nM 8.49nM 
Chloroquine 100mg/ml 220ug/ml 75.17ug/ml 25.68ug/ml 8.77ug/ml 
MG-132 10mM 22.4uM 7.69uM 2.64uM 0.91uM 
Simvastatin 10mM 22.8uM 7.87uM 2.71uM 0.94uM 
Nystatin 5mg/ml 11.6ug/ml 4.02ug/ml 1.39ug/ml 0.48ug/ml 
FCCP 20mM 47.2uM 16.44uM 5.73uM 1.99uM 
PuAD 500uM 1200nM 420nM 147nM 51.45nM 





RNA Extraction and Supplemental DNase Treatment 
 Total RNA was obtained from cells via RNA extraction (Promega, ReliaPrep 
RNA tissue Miniprep System Ref. Z6111). Cells were washed in PBS (Gibco, Dulbecco's 
Phosphate Buffered Saline Ref. 14190-144), lysed in 1-thioglycerol solution, after which 
RNA was sequestered using 100% isopropanol. DNase treatment along with several RNA 
and column washes were performed according to the Promega protocol. There were 
slight deviations from the protocol in the number of cells collected and volume of lysis 
buffer used. RNA was eluted with DEPC treated molecular grade water (Ambion, P/N. 
AM9920, L/N. 1508030), where concentrations of ~15ng/ul and the 260/280 purity (1.7-
2.1) were verified (Figure 2) using a Nanodrop (Thermoscientific, Nano Drop One). A 
second application of DNase (Promega, RQ1 RNase free DNase Ref. M610A) in 10x 
reaction buffer (Ref. M198A) was administered to all RNA samples (15ng/ul) that met 
criteria. 
 
Figure 2. Measurements via Nanodrop provide RNA concentration (ng/ul), and purity in absorbance ratios 
at 260/280 and 260/230. Quantifications are displayed for three samples. Sample 1 was excluded from 








 Synthesis of cDNA (Promega, GoScript Reverse Transcription System Ref. 
A5000) for both CV4a and CV17q cell lines per condition (2D vs 3-D) was achieved by 
annealing random hexamers, according to manufacturer instructions, to purified DNase 
treated RNA. Purified RNA was diluted to a concentration of 15ng/ul. A master mix was 
prepared in proper proportion(s): RNA, DEPC treated H2O, GoScript 5x reaction buffer, 
2.5mM MgCl2, 0.5mM PCR Nucleotide mix, RNasin, and Goscript Reverse 
Transcriptase enzyme. A negative control mix was made to exclude the reverse 
transcriptase enzyme for validity of RNA, contaminant free from genomic DNA (Figure 
3). All samples were placed in a Bio-Rad T100 thermocycler with annealing, extension, 
and inactivation temperatures of 25°C for 5 minutes, 42°C for one hour, and 70°C for 15 
minutes, respectively. Final cDNA product was stored at -4°C. 
 
Figure 3. EEF1A1 (lanes 2,3), RPL27 (lanes 4,5), MAPT-tot-2 (lanes 6,7), and ODZ2 (lanes 8,9) primer 
sets were used as an experimental control for reverse transcription. (A) PCR products loaded on 2% 
agarose gel in TBE. Lanes 3, 5, 7, 9 display bands where reverse transcriptase enzyme was excluded from 
the reaction indicating genomic DNA contamination. (B) Successful PCR amplification of positive RT 
enzyme Lanes 2, 4, 6, 8; and little to no amplification of genomic DNA in the negative control lanes 3, 5, 7, 
9. Amplification of problematic cDNA samples and corresponding genes via PCR demonstrates a 





Primer Sets, Polymerase Chain Reaction and Gel Electrophoresis 
 Genes were selected based on bioinformatics from Cahoy et al. (2008). Primer 
sets were obtained through Harvard Primer bank (Table S1). Forward and reverse 
primers were re-suspended/diluted 1/20 in molecular grade H2O. To avoid conjecture, 
primers have been screened via gel electrophoresis (Figure 4; Table S1). Primer sets 
were excluded/replaced if PCR products yielded bands that a) fell outside expected 
sequence length, b) largely generated primer dimers, or c) produced multiple band sizes. 
A master mix was made with 1ul cDNA, 7ul molecular grade H2O, and 10ul 2x 
EconoTaq per reaction. 18ul master mix was amalgamated with 2ul combined forward 
and reverse primers diluted 1/20. cDNA was diluted with 100ul H2O regardless of 
concentration. Reactions were completed in a Bio-Rad T100 thermocycler at 94°C, 52°C, 
and 72°C. Primers were prepared in 96-well deep well plates (Table 3). Agarose gels 
were prepared with 2% agarose (KSE Scientific, Molecular Biology Grade Agarose) in 
1x TBE buffer. Gels were run at 100 volts for ~45 minutes, and visualized in Alpha 






Figure 4. Gene placement map. Primers were selected based on cell specific gene expression. Primers were 
screened; yellow boxes and green arrows identify possible inconsistencies with primer sets. Could be non-





Table 3. Plate layout of forward and reverse primer sets. 2ul forward and 2ul reverse primers were 
prepared in 196ul molecular grade H2O. Column 1 rows A-H contain MAPT primer sets. Column 2 rows 
A-D contain housekeeping gene primer sets. Column 2 rows E-H, Column 3 rows A-H, Column 4 A-B 
contain neuronal gene primer sets. Column 4 rows C-H, Column 5 rows A-H contain astrocytic gene 
primer sets. Column 6 rows A-H contain oligodendrocytic gene primer sets. Primer sequences are 
described in detail in the supplemental gene sequence Table S1.  
 1 2 3 4 5 6 
A MAPT-tot GAPDH Syt1 Satb Tnc Mobp 
B MAPT-3R TBP Crh Sla_new-1 Emp1 Cpm 
C MAPT-4R RPL27 Dlx* GFAP Tgif2 Adamts4 
D MAPT-tot-2 EEF1A1 DLX_2 Sult1a1* Ptx3 Enpp6_2 
E MI-MAPT-3R4R TUB1A Pgm2l1 SULT1A1_2 Agx2l1 Enpp6_3 
F MAPT-set-tot Syn1 Odz2 Pla2g7 Tcfcp2l1 Mog 
G MAPT-set-3R Neurod6 Vip ALDH1L1_1 Dmp1 Ugt8a 







Cell Specific Gene Targeting with Reporter Plasmids 
HiFi assembly 
 Each promoter sequence and EGFP was synthesized by PCR and inserted by HiFi 
assembly into the AAVS1 SA-2A-puro-pA donor plasmid at the SalI restriction site 
(Addgene plasmid # 22075; Hockemeyer et al. 2009). Each resulting plasmid was co-
transfected with AAVS1-targeting sgRNA/Cas9-D10A dual nickase CRISPRs (px462, 
Addgene plasmid #62987) into neural progenitor cells, then selected for stable integration 
by puromycin. The following well-described synthetic gene promoters/enhancers 
(sourced from VectorBuilder, Table 4) were selected as cell specific markers: PRNP (all 
neurons, Weber et al. 2001); SYN1 (mature neurons, Glover et al. 2002); GFAP 
(astrocytes, Brenner et al. 1994); CNP (oligodendrocytes/Schwann cells, Gravel et al. 
1998); and EEF1A1 (all cell types, Mizushima and Nagata, 1990). Cell type identity was 
confirmed by fluorescence microscopy (cell morphology) and by immunostaining with 
commonly used antibodies against these cell types (e.g. anti-GFAP, anti-Tuj1, anti-CNP, 
anti-tau etc.). Promoters, and PRP-TRE3G-EGFP-CV fragments were amplified 
separately via PCR (Figure 5). Promoter sequences (Figure 5a) together with EGFP-
Cloning site fragments (Figure 5b) were HiFi assembled into the AAVS1-TRE vector 
backbone (Figure 5c). All DNA sequences (10ng/ul) were combined with the HiFi 
Assembly Master Mix according to manufacturer protocol (NE Builder HiFi DNA 





50°C for 15 minutes. Samples were stored at -20°C. Once the plasmid was validated, the 
DNA was transformed into chemically-competent E. coli (Stbl3 cells). 
Table 4. Primer sets used for plasmid construction. Promoter sequences, forward and reverse were used to 
amplify the promoter region of interest. Kozak sequences were used to amplify fully constructed plasmid 
cassettes.  
Reference # Primer Name Sequence Tm (50mM 
NaCl) 
194207966 EF1_Promoter_F 5’- GAT GCG GTG GGC TCT ATG GGG GCT 
CCG GTG CCC GTC -3’ (38bp) 
74.9°C 
194207967 EF1_Promoter_R 5’- TAC AAA CTT GTC ACG ACA CCT GAA 
ATG GAA GAA AAA AAC TTT GAA CC -3’ (47 
bp) 
64.2°C 
194207968 EF1Kozak_F 5’- GGT GTC GTG ACA AGT TTG TAC AAA 
AAA GCA G -3’ (31 bp) 
60.2°C 
194207969 EF1Kozak_R 5’- CCT AGT AAA GCT TAG TAC TGT ACC 




5’- GAT GCG GTG GGC TCT ATG GGC TGC 




5’- CCA TGG TGG CCT GCG CTC TCA GGC 
ACG AC -3’ (29 bp) 
70.8°C 
194207972 SYN1Kozak_F 5’- GAG AGC GCA GGC CAC CAT GGT GAG 
CAA G -3’ (28 bp) 
68.1°C 
194207973 SYN1Kozak_R 5’- CCT AGT AAA GCT TAG TAC TGT ACC 




5’- GAT GCG GTG GGC TCT ATG GGG AGC 




5’- CCA TGG TGG CCC TGC TCT GGC TCT 
GCT C -3’ (28 bp)  
69.5 °C 
194207976 GFAPKozak_F 5’- CCA GAG CAG GGC CAC CAT GGT GAG 
CAA G -3’ (28 bp) 
68.0 °C 
194207977 GFAPKozak_R 5’- CCT AGT AAA GCT TAG TAC TGT ACC 
ACA TTT GTA GAG GTT TTA CTT G -3’ (46 
bp)  
61.9 °C 
198442191 CNP_Promoter_F 5’-GAT GCG GTG GGC TCT ATG GGC CCA 






Reference # Primer Name Sequence Tm (50mM 
NaCl) 
198442192 CNP_Promoter_R 5’-CCA TGG TGG CGC TTG TGT TCT GTG 
TAA GAA GGG-3’ (33 bp) 
66.2°C 
198442193 CNP_KOZAK 5’- GAA CAC AAG CGC CAC CAT GGT GAG 
CAA G-3’ (31bp) 
65.4°C 
 
Figure 5. HiFi Assembly. (a) PCR product displays successful amplification of Syn1 (469bp) and EEF1A1 
(1179bp) promoter sequences. Lane 1 contains 2-log ladder. (b) Based on the 2-log ladder, both bands 
appear to be about 1.1 kbp. Prepped for HiFi assembly, Lane 2 indicates SYN1Kozak-EGFP-T2A in 
EGFP-T2A-Cloning Site_pA fragment and Lane 3 indicates EF1Kozak-EGFP-T2A in EGFP-T2A-Cloning 
Site_pA fragment. (c) Illustration of AAVS1 plasmid backbone complete with insertion of HiFi assembled 
cell type specific promoter (Red) and EGFP (Green) sequences. Transfection of assembled cassettes into 
NPCs identified cell types based on EGFP expression within cells exclusively expressing the corresponding 
reporter gene promoter. An EcoRV restriction site (Yellow) was included for prospective CRISPR insert 






Transformation into competent E. coli. 
 Chemically-competent Stbl3 E. coli cells were thawed on ice. 2ul of assembled 
HiFi product was added to these cells and incubated on ice for 30 minutes. The cells were 
then heat shocked for 30 seconds at 42°C and placed back on ice for 2 minutes. 950ul of 
SOC media was added to the tube at room temperature. The tube was incubated at 37°C, 
shaken for 1 hour. 100ul of transformed cell suspension was incubated overnight at 37°C 
on LB and LB+AMP agar plates for antibiotic selection and subsequent bacterial direct 
PCR for confirmation of successful transformation.  
Transient transfection and differentiation of NPCs (day 0 - day 28) 
 E. coli cells were selected for successful transformation by bacterial direct PCR, 
and lysed. Assembled plasmid was harvested and then transfected with LipoD293 in 
confluent 24-well adherent plates of NPC cultures. LipoD293 transfection agent in 
DMEM was mixed together (per condition/promoter) with 500ng sgRNA A, 500ng 
sgRNA B, and 1ug AAVS1 assembled plasmid and incubated at 37°C for 15 minutes. 
Cell media was changed to NPCb + FGF and then treatment of 50ul LD293 (per 
condition) was administered to each designated well. Cultures were incubated at 37°C for 
~8 hours. LD293 media was replaced with NPCb + FGF and cells were allowed to 
proliferate for ~48 hours before passaging to 48-well and 96-well plates for subsequent 
puromycin selection and differentiation via FGF withdrawal. In 3D cultures, NPCs were: 
transfected, allowed to grow confluent, suspended in NPCb + FGF, transferred to plates 





Selection with puromycin 
 Puromycin antibiotic was used in concentrations of 2ng/ul, 1ng/ul, and 0.5ng/ul 
for the selection of successfully transfected neural progenitor cells. After treatment with 
puromycin, the cells were left to grow to confluency. Once cells were confluent, FGF 
withdrawal was performed to initiate cell differentiation. 
Fluorescent imaging 
 Zeiss Axio ObserverZ1 inverted fluorescence microscope with digital camera 
aided in the visualization of transfected cells. After differentiation was initiated, cells 
were imaged every 3-5 days, beginning with day 0, for at least 28 days. 
Drug Treatments and Cell Viability 
 Treatments were administered to cells according to the plate layout in Table 5. 
Resazurin/Resorufin assay was performed to determine cell viability. Drug treatments 
were prepared as four serial dilutions by a dilution factor of 1/3. To prepare concentration 
(A), 3ul of stock concentration was diluted into 500ul NPCb + 0.1% DMSO. 
Concentrations (B), (C), (D) were prepared by serial dilution of 200ul concentration (A) 
into 400ul NPCb (Table 2). On day 28 of differentiation, cells were replated and treated 
in triplicate for each concentration per condition. After 48 hours media plus drug 
treatments were removed and replaced with NPCb. Resazurin was prepared at 
12.56mg/ml in HBSS and further diluted 1/5 in 10ml HBSS. Of the Resazurin dilution, 
37.5ul was added to 150ul NPCb. Plates were incubated for 2 hours at 37°C and read on a 





Table 5. Two 96-well plates containing ~50,000 cells/well were loaded with drug treatments and controls 
according to this plate layout. Color coded for drug concentrations. Serial dilutions were performed and 
cells were treated in triplicate. 
Concentration A Concentration B Concentration C Concentration D 
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 Extracted protein samples from drug treated cells were loaded at 0.4ug/ul on 4% 
Bis-Tris Midi Gels (NuPAGE, Ref. WG1403BX10); run at 200V for 40 minutes in MES-
SDS (NuPAGE) running buffer; transferred to membrane using tris-glycine-20% 
methanol and kept there for 2 hours at 40V. Protein samples were standardized to a BCA 
assay. Membranes were blocked in milk for 45 minutes, washed, and incubated overnight 
in primary antibody: 1-2,000 (Sigma, Polyclonal Rabit, anti-tau) or 1-25,000 (Millipore, 
MAB 1501 Monoclonal mouse, anti-actin) in 5% milk/TBST. Membranes were washed 
with TBS in 0.5% TWEEN20 and incubated with LC3/Tau secondary antibody (Vector 
Labs, goat anti-rabbit HRP PI-1000) or Actin secondary antibody (Vector Labs, horse 
anti-mouse HRP PI-2000). Western blot images (Figure. 6) were visualized on a C-DiGit 







Figure 6. Western blot displays Total tau, Actin, LC3-I, and LC3-II protein accumulation within control 
(Top) CV4a or diseased (Bottom) CV17q cells. Lane 1 represents chemiluminescent protein MW 
standards. Lanes 2-12 represent individual drug treatments with conditioned protein accumulation. 
Concentrations “B” and “D” were selected for each treatment based on a resazurin cell viability assay. 
Measurements of band pixel density were performed in ImageJ. One measurement was taken to include all 






Gene Expression Quantification and Statistical Analysis 
 Band length of cDNA samples was determined by gel electrophoresis and pixel 
density was analyzed in ImageJ analysis software (Rasband, W.S., ImageJ, U. S. National 
Institutes of Health, Bethesda, Maryland, USA). A frame with a set area of 0.50 (Figure 
7) was used to measure and quantify pixel density. Background measurements were 
averaged and subtracted from each measurement. Background subtracted measurements 
were normalized to constitutive housekeeping genes (GAPDH, TBP, RPL27, EEF1A1). 
Collected data was organized in Excel and statistically analyzed in SPSS. A heat map 
was produced to describe the entire panel of genes as compared to CV4a controls (Day 0 
NPCs). Individual sample t-test was performed on pixilation data to compare levels of 






Figure 7. Example of analyzed gel for gene expression profile. (TOP) Representative image of 2% gel after 
being loaded with PCR amplified cDNA and targeted primer sets. (BOTTOM) Pixel density was measured 
inside a fixed area represented by the numbered yellow boxes. Gene expression was determined to be up or 







Protein Quantification and Statistical Analysis 
 Protein levels were analyzed in ImageJ analysis software. A frame with a set area 
(Figure 8) was used to measure and quantify pixel density of individual bands per lane. 
Background measurements were averaged and subtracted from each measurement. 
Background subtracted measurements were normalized to constitutive actin as a control. 
Data was statistically analyzed in Excel or SPSS. First, an individual sample t-test was 
performed to compare baseline vehicle controls between CV4a and CV17q cell lines. 
One-way ANOVA was performed to compare protein levels between vehicle and 
selected drug concentrations (B, D) within the CV4a or CV17q cell line. Any significant 
changes in protein levels were tested for homogeneity of variance. Protein data that were 
found to have equal variance were further analyzed by Bonferroni correction, or data that 
were found not to have equal variance were further analyzed by Dunnett’s T3 test. 
 
Figure 8. Example of analyzed gel for protein expression after drug treatments. Pixel density was measured 
inside a fixed area represented by the numbered yellow boxes. Protein levels were determined to be up or 







Vehicle Baseline Control between Cell Lines 
 An individual sample t-test was first performed in order to compare the means of 
CV4a vs CV17q independent vehicles (NPCb + DMSO) between cell lines (Figure 9). 
This provided statistical evidence, assuming the equality of variance, that these: LC3-
II/LC3-I (p>0.001), MAPT5 (p=0.043), and total tau (p=0.041) associated population 
means were significantly different.  
 
Figure 9. Baseline vehicle graph normalized to actin, or LC3-II/LC3-I ratio comparing CV4a to CV17q in 
normal media conditions. Boxes outline significance. There was a decreased of LC3-II/LC3-I ratio in 
CV17q (p<0.001), MAPT5 was increased in CV17q (p=0.043), and there was more total tau in CV17q 
(p=0.041). 
Cell Viability per Drug Treatment 
 One-way ANOVA was performed to compare vehicle with four concentrations 
within the CV4a (Figure 10) or CV17q (Figure 11) cell line. Any significant changes in 
cell viability were tested for homogeneity of variance and further analyzed by Dunnett’s 

























Simvastatin, Nystatin, FCCP, and PUaD measurements were found to have equal 
variance and therefore, Bonferroni corrected. Data that were found to not have equal 
variance, within the CV4a line, (SCD1, SPAUTIN1, BAFA1, Chloroquine, Vorinostat) 
were analyzed using Dunnett’s T3 test. Within the CV17q line, only Chloroquine 
measurements were found to have equal variance and subsequently Bonferroni corrected. 
Data that were found to not have equal variance (Rapamycin, Torin1, SCD1, SPAUTIN1, 
BAFA1, MG-132, Simvastatin, Nystatin, FCCP, PuAD, Vorinostat) were analyzed using 
Dunnett’s T3 test.   
Within the CV4a line (Figure 10):  
 Rapamycin caused a decrease in LC3-II/LC3-I ratio by concentration D when 
compared to control (assumed equal variance; p=0.009). Torin1 induced a decrease of 
LC3-II/LC3-I by concentration D when compared to control (not assumed equal 
variance; p>0.001). Spautin1 had no significant changes in any protein levels by any 
concentration. BafA1 showed a significant increase in LC3-II/LC3-I ratio by 
concentration B (not assumed equal variance; p=0.017). Chloroquine exhibited increase 
of LC3-II/LC3-I ratio by concentration B (equal variance assumed; p=0.006). MG-132 
displayed a significant increase in LC3-II/Actin by concentration B (equal variance not 
assumed; p=0.018), as well as LC3-II/LC3-I ratio increase by concentration B (p=0.003) 
but had a significant decrease by concentration D (p=0.030) (equal variance assumed), 
and an increase in MAPT4 by concentration B (equal variance assumed; p=0.019). 
Simvastatin showed a decrease in LC3-II/LC3-I by concentration D (not assumed equal 





concentration D (not assumed equal variance; p=0.001). PuAD decreased the LC3-
II/LC3-I ratio by both concentrations B and D (assumed equal variance; p=0.031; 
p=0.004). PuAD also exhibited increases in MAPT4 by concentration B (assumed; 
p=0.004), MAPT5 by concentrations B and D (assumed; p=0.001; p=0.004), and total tau 
accumulation by concentration B (assumed; p=0.015). Vorinostat showed a decrease in 
LC3-II/LC3-I by concentrations B and D (assumed; p=0.012; p=0.006). Vorinostat also 
demonstrated increase in MAPT2 by concentration B (assumed equal variance; p=0.032), 
MAPT3 by concentration B (assumed; p=0.017), MAPT5 by concentration B (not 
assumed equal variance; p=0.029), and total tau accumulation by both concentrations 
(assumed; p=0.009; p=0.028).  
Within the CV17q line (Figure 11): 
 Rapamycin had no significant effect on protein levels by any concentration when 
compared to control. Torin1 caused a decrease in MAPT2 accumulation by concentration 
D (assumed equal variance; p=0.031). Spautin1 caused an increase in MAPT2 and 
MAPT3 accumulation by concentration D (assumed equal variance; p=0.018, p= 0.047 
respectively). BafA1 showed a significant increase in LC3-II/LC3-I ratio by 
concentration B (not assumed equal variance; p=0.029). BafA1 also caused a decrease in 
MAPT1 by concentration D (assumed; p=0.004), MAPT2 by concentration D (assumed 
equal variance; p=0.002), MAPT3 by concentration D (assumed; p=0.005), MAPT5 by 
both concentrations (not assumed equal variance; p=0.031; p=0.015), and total tau 
accumulation by concentration D (assumed equal variance; p=0.013). Chloroquine 





concentration D (not assumed equal; p=0.001), and MAPT3 by concentration D 
(assumed; p=0.041). MG-132 had a significant decrease in MAPT1 by concentration D 
(assumed; p>0.001), as well as an increase in MAPT2 and MAPT4 by concentration B 
(assumed; p=0.002; p=0.001). Simvastatin showed a decrease in MAPT1 by 
concentration D (assumed; p=0.001) and MAPT2 by concentration D (assumed equal 
variance; p=0.045). Interestingly, Simvastatin exhibited a decrease in LC3-I protein when 
compared to control in concentration D (assumed; p=0.041). Nystatin displayed a 
significant increase in MAPT1, MAPT2, and MAPT3 by concentration B (assumed; 
p=0.001, p=0.007, p=0.004). PuAD exhibited increases in MAPT1 by concentrations B 
and D (assumed; p<0.001; p=0.005), MAPT2 by concentrations B and D (assumed equal; 
p<0.001; p=0.007), MAPT3 by concentration B only (assumed; p<0.001), MAPT4 by 
concentrations B and D (assumed; 0.000; p=0.003), MAPT5 by concentration B only 
(assumed; p=0.008), and total tau by both concentrations B and D (assumed equal 
variance; p<0.001; p=0.022). Vorinostat displayed an increase in MAPT1 by 
concentrations B and D (assumed equal; p<0.001; p<0.001), MAPT2 by concentrations B 
and D (assumed equal; p<0.001; p<0.001), MAPT3 by concentrations B and D (assumed 
equal; p<0.001; p<0.001), MAPT4 by concentrations B and D (assumed equal; p<0.001; 
p<0.001), MAPT5 by concentrations B and D (assumed equal; p<0.001; p=0.001), and 
total tau accumulation by concentrations B and D (assumed equal variance; p<0.001; 
p<0.001). 
 To validate drug efficacy, treatments were first tested for significant correlation to 





resazurin into resorufin in four different concentrations of previously described drug 
treatments (Table 2; Table 4) within two cell lines (CV4a, CV17q). Plates were 
incubated with resazurin and read for the absorbance of resorufin at λ 562nm. Cell 
viability results, as well as protein accumulation in cultured iPSC derived neural cells 









A B C D
 Figure 10. Cell viability by resazurin in the CV4a cell line. Each drug was used in four concentrations as 
A, B, C, or D. NPCb + 0.1% DMSO was the control. Rapamycin, Torin1, MG-132, Simvastatin, Nystatin, 
FCCP, and PuAD measurements were normally distributed and further analyzed using a Bonferroni 
correction test. Data found not to be normally distributed (SCD1, Spautin1, BafA1, Chloroquine, 
Vorinostat) were analyzed using the Dunnett’s T3 test. Rapamycin showed significant change in 
concentration C; Torin1 showed significant changes in concentrations B,C, and a trend for concentration A; 
SCD1 showed significant changes in concentrations A,B,C,D; Spautin1 showed significant changes in 
concentrations B,C, and a trend in concentration A; BafA1 showed significant changes in concentrations 
A,B,C,D;  Chloroquine showed significant change in concentrations C,D; MG-132 showed significant 
changes in concentrations A,B,C; Simvastatin showed no significant changes from control; Nystatin 
showed no significant change from control; FCCP showed a trend in concentration A (p=0.057); PuAD 
showed significant changes in concentrations A,B; Vorinostat showed significant changes in 






Figure 11. Cell viability by resazurin in the CV17q cell line. Each drug was used in four concentrations as 
A, B, C, or D. NPCb + 0.1% DMSO was the control. Chloroquine measurements were normally distributed 
and further analyzed using a Dunnett’s T3 test. Data found not to be normally distributed (Rapamycin, 
Torin1, SCD1, Spautin1, BafA1, MG-132, Simvastatin, Nystatin, FCCP, PuAD, Vorinostat) were analyzed 
using the Bonferroni correction test. Rapamycin showed no significant change from control; Torin1 
showed significant changes in concentrations A,B,C; SCD1 showed significant changes in concentrations 
A,B,C; Spautin1 showed significant changes in concentrations B,C; BafA1 showed significant changes in 
concentrations A,B,C,D;  Chloroquine showed no significant change from control; MG-132 showed 
significant changes in concentrations A,B,C; Simvastatin showed significant changes in concentration A 
and a strong trend in concentration B (p=0.058); Nystatin showed no significant change from control; 
FCCP showed significant changes in concentrations A,C; PuAD showed significant changes in 














Protein Accumulation Varies with Condition and Cell Line 
 One-way ANOVA was performed to compare vehicle with selected 
concentrations (B, D) within the CV4a or CV17q cell lines. Any reported changes in 
protein level were tested for homogeneity of variance and further analyzed by Dunnett’s 
T3, or Bonferroni corrected. 
Rapamycin 
 In four concentrations (A=5.48uM, B=1.83uM, C=0.61uM, D=0.20uM) (Figure 
12) CV4a cells showed significant cell viability decrease, assessed by resazurin, in 
0.61uM concentration, when normalized to control (Figure 12a). Western blot analysis 
revealed a decrease in LC3-II/LC3-I ratio after treatment with 0.20uM (Figure 12b). 
Treating CV17q cells with Rapamycin (Figure 12) showed no significant changes in cell 
viability by resazurin for any conditions (Figure 12a). Western blot results showed no 
significant changes in LC3-I or LC3-II protein accumulation (Figure 12b). Individual tau 
and total tau analyses (Figure 12c) exhibited no significant change in tau accumulation 






Figure 12. Effects of treating cell lines with Rapamycin in four concentrations. (a) Treatment with 
rapamycin shows cell viability by resazurin in CV4a (n=6 Control, n=3 Treatment) and CV17q (n=10 
Control, n=5 Treatment) cell lines. There was a decrease in CV4a cell viability by 0.61uM (p=0.007). (b) 
Western blot results show LC3-I (left) and LC3-II (right) accumulation normalized to actin or LC3-II/LC3-
I ratio. Concentration D affects LC3-II/LC3-I accumulation in CV4a (p=0.009) (c) Individual tau band and 
total tau analyses show no effect on tau protein levels. Graph, mean ± SEM, n=9 Treatment, n=72 Control. 
Torin1  
 In four concentrations (A=2.04uM, B=0.68uM, C=0.23uM, D=0.08uM) (Figure 
13) CV4a showed a decrease in cell viability by 0.68uM, and 0.23uM normalized to 
control (Figure 13a). Western blot results showed that 0.68uM has a decreasing effect on 
LC3-II/LC3-I ratio (Figure 13b). Effects of treating CV17q cells with Torin1 (Figure 
13) showed a decrease in cell viability by 2.04uM, 0.68uM, and 0.23uM (Figure 13a). 
Western blot results show no change in LC3 levels (Figure 13b). Individual tau and total 






Figure 13. Effects of treating cell lines with Torin1 in four concentrations. (a) Treatment with Torin1 
showed cell viability by resazurin in CV4a (n=6 Control, n=3 Treatment) and CV17q (n=10 Control, n=5 
Treatment). There was a change in CV4a cell viability by 0.68uM (p=0.014), 0.23uM (P=0.021) and a 
change in CV17q cell viability by 2.04uM (p=0.008), 0.68uM (p=0.001), and 0.23uM (p=0.034). (b) 
Western blot results showed LC3-I (left) and LC3-II (right) accumulation normalized to actin or ratio of 
LC3-II/LC3-I. 0.08uM affects LC3-II/LC3-I ratio in CV4a (p<0.001). (c) Individual tau band and total tau 
analyses showed a decreasing effect on MAPT2 levels in CV17q cells (p=0.031). Graph, mean ± SEM, n=9 
Treatment, n=72 Control. 
SCD1  
 In four concentrations (A=20.8uM, B=7.0uM, C=2.36uM, D=0.79uM) (Figure 
14) CV4a showed significant decrease in cell viability by resazurin for 20.8uM, 7.0uM, 
2.36uM, and 0.79uM normalized to control. Effects of treating CV17q cells with SCD1 
showed significant changes in cell viability (Figure 14) by resazurin in 20.8uM, 7.0uM, 
and 2.36uM. Decreased cell viability in all concentrations with the exception of 0.79uM 






Figure 14. Effects of treating cell lines with SCD1 in four concentrations. Treatment with SCD1 show cell 
viability by resazurin in CV4a (n=6 Control, n=3 Treatment) and CV17q (n=10 Control, n=5 Treatment). 
There was a decrease in CV4a cell viability by 20.8uM (p=0.005), 7.0uM (p<0.001), 2.36uM (p<0.001), 
and 0.79uM (p=0.015). There was a change in CV17q cell viability by 20.8uM (p=0.001), 7.0uM 
(p=0.001), and 2.36uM (p=0.005). 
 
Spautin1  
 In four concentrations (A=42.4uM, B=14.3uM, C=4.85, D=1.64uM) (Figure 15) 
CV4a showed a decrease in cell viability by resazurin in 14.3uM normalized to control 
(Figure 15a). Western blot showed no changes to protein accumulation (Figure 15b). 
Effects of treating CV17q cells with Spautin1 (Figure 15) showed a decrease in cell 
viability by14.3uM, and 4.85uM (Figure 15a). Western blot showed no significant 
changes in LC3 protein levels (Figure 15b). Individual tau and total tau analyses (Figure 
15c) exhibited a change in MAPT2 and MAPT3 protein levels at 1.64uM within the 






Figure 15. Effects of treating cell lines with Spautin1 in four concentrations. (a) Treatment with Spautin1 
show cell viability by resazurin in CV4a (n=6 Control, n=3 Treatment) and CV17q (n=10 Control, n=5 
Treatment). There was a change in CV4a cell viability by 14.3uM (p<0.001). There was a decrease in 
CV17q cell viability by 14.3uM (p=0.004), and 4.85uM (p<0.001). (b) Western blot results show LC3-I 
(left) and LC3-II (right) accumulation normalized to actin or LC3-II/LC3-I ratio. There were no changes in 
either cell line at either concentration. (c) Individual tau band and total tau analyses show 1.64uM has an 
effect on MAPT2 (p=0.018), and MAPT3 (p=0.047) protein levels in CV17q cells. Graph, mean ± SEM, 
n=9 Treatment, n=72 Control. 
 
Bafilomycin A1  
 In four concentrations (A=216nM, B=73.44nM, C=24.97nM, D=8349nM) 
(Figure 16) CV4a showed significant decrease in cell viability by resazurin for all 
concentrations when normalized to control (Figure 16a). Western blot showed that there 
was no significant change in LC3-I (Figure 16b) and a significant decrease in LC3-
II/LC3-I ratio by 73.44nM (Figure 16b). Effects of treating CV17q cells with BAFA1 
(Figure 16) showed significant decrease in cell viability by all concentrations when 
compared to control (Figure 16a). Western blot showed no change in LC3-I and 
significant increase in LC3-II/LC3-I ratio by 73.44nM (Figure 16b). Individual tau and 





MAPT5, and total tau protein within the CV17q line at 8.49nM and an increase in 
MAPT5 by 73.44nM. 
 
Figure 16. Effects of treating cell lines with BAFA1 in four concentrations. (a) Treatment with BafA1 
showed cell viability by resazurin in CV4a (n=6 Control, n=3 Treatment) and CV17q (n=10 Control, n=5 
Treatment). There was a decrease in CV4a cell viability by resazurin at 216nM (p<0.001), 73.44nM 
(p<0.001), 24.97nm (p<0.001), and 8.49nM (p=0.004). There was a decrease in CV17q cell viability by all 
four concentrations compared to control (p=0.009), (p<0.001), (p<0.001) (p=0.001). (b) Western blot 
results show LC3-I (left) and LC3-II (right) accumulation normalized to actin and LC3-II/LC3-I. 73.44nM 
affects LC3-II/LC3-I ratio in CV4a and CV17q lines (p=0.017), (p=0.029) (c) Individual tau band and total 
tau analyses show a decrease in MAPT1 (p=0.004), MAPT2 (p=0.002), MAPT3 (p=0.005), MAPT5 
(p=0.015), and total tau protein (p=0.013) within the CV17q line at 8.49nM and an increase in MAPT5 at 
73.44nM (p=0.031). Graph, mean ± SEM, n=9 Treatment, n=72 Control. 
 
Chloroquine  
 In four concentrations (A=220ug/mL, B=75.17ug/mL, C=25.68ug/mL, 
D=8.77ug/mL) (Figure 17) CV4a showed a decrease in cell viability by resazurin for 
25.68ug/ml, and 8.77ug/ml normalized to control (Figure 17a). Western blot showed no 
significant change in LC3-I levels. There was an increase of LC3-II/LC3-I ratio after 





Chloroquine (Figure 17) showed no significant change in cell viability by resazurin for 
any concentration (Figure 17a). Western blot showed no change in LC3-I or LC3-II 
(Figure 17b). Individual tau and total tau analysis (Figure 17c) exhibited a decrease in 
MAPT1, MAPT2, and MAPT3 after treatment with 8.77ug/mL within CV17q. 
 
Figure 17. Effects of treating cell lines with Chloroquine in four concentrations. (a) Treatment with 
Chloroquine show fold changes in cell viability by resazurin in CV4a (n=6 Control, n=3 Treatment) and 
CV17q (n=10 Control, n=5 Treatment). There was a decrease in CV4a cell viability by 25.68ug/ml 
(p<0.001), and 8.77ug/mL (p=0.006). There were no reported changes in CV17q cell viability by any of the 
four concentrations as compared to control. (b) Western blot results show LC3-I (left) and LC3-II (right) 
accumulation normalized to actin or ratio of LC3-II/LC3-I. 75.17ug/mL showed an increase in LC3-
II/LC3-I ratio in CV4a (p=0.006). (c) Individual tau band and total tau analyses show an increase within the 
CV17q line of MAPT1 (p=0.008), MAPT2 (0.001), and MAPT3 (p=0.041) after treatment with 8.77ug/mL 
and no change in CV4a. Graph, mean ± SEM, n=9 Treatment, n=72 Control. 
 
MG-132  
 In four concentrations (A=22.4uM, B=7.69uM, C=2.64uM, D=0.91uM) (Figure 
18) CV4a and CV17q displayed a decrease in cell viability by resazurin for 22.4uM, 
7.69uM, and 2.64uM normalized to control (Figure 18a). Western blot showed no 





show a significant effect on LC3-II/LC3-I within CV4a cells. Individual tau and total tau 
analyses normalized to actin (Figure 18c) exhibited a significant increase in MAPT4 at 
7.69uM in CV4a. Tau analysis also exhibited an increase in MAPT1, MAPT2, and 
MAPT4 in CV17q. The effect of MG-132 on cell viability may be caused by higher 






Figure 18. Effects of treating cell lines with MG-132 in four concentrations. (a) Treatment with MG-132 
show fold changes in cell viability by resazurin in CV4a (n=6 Control, n=3 Treatment) and CV17q (n=10 
Control, n=5 Treatment). There was a decrease in CV4a cell viability by 22.4uM (p<0.001), 7.69uM 
(p<0.001), and 2.64uM (p=0.002). There was a decrease in CV17q cell viability by 22.4uM (p<0.001), 
7.69uM (p<0.001), and 2.64uM (p<0.001). (b) Western blot results show LC3-I (left) and LC3-II (right) 
accumulation normalized to actin or ratio of LC3-II/LC3-I. 7.69uM (p=0.003) and 0.91uM (p=0.030) 
showed an increase in LC3-II/LC-I accumulation in CV4a only. (c) Individual tau band and total tau 
analyses normalized to actin show an increase in MAPT4 (p=0.019) after treatment with 7.69uM in CV4a. 
Tau analysis also exhibited a decrease within the CV17q line, in MAPT1 (p<0.001) by 0.91uM, MAPT2 




 In four concentrations (A=22.8uM, B=7.87uM, C=2.71uM, D=0.94uM) (Figure 
19) CV4a showed no significant changes in cell viability by resazurin in any condition 
(Figure 19a). Within the CV4a cell line, Western blot showed a significant decrease in 
LC3-II/LC3-I after treatment with 0.94uM (Figure 19b). Effects of treating CV17q cells 
with Simvastatin (Figure 19) showed a decrease in cell viability by resazurin in 22.8uM 
(Figure 19a). Western blot showed significant decrease in LC3-I protein accumulation at 





normalized to actin (Figure 19c) exhibited no change in tau levels within the CV4a line 
at either concentration when compared to control. Tau analysis exhibited a significant 
decrease in MAPT1, and MAPT2, within CV17q at 0.94uM. 
 
Figure 19. Effects of treating cell lines with Simvastatin in four concentrations. (a) Treatment with 
Simvastatin show fold changes in cell viability by resazurin in CV4a (n=6 Control, n=3 Treatment) and 
CV17q (n=10 Control, n=5 Treatment). There was no change in CV4a cell viability by any concentration 
and treatment showed a decrease in CV17q cell viability at 22.8uM (p=0.005). (b) Western blot results 
show LC3-I (left) and LC3-II (right) accumulation normalized to actin or ratio of LC3-II/LC3-I. 0.94uM 
seemed to have a decreasing effect on LC3-II/LC3-I ratio (p=0.035) in CV4a. Cells treated with 0.94uM 
also displayed a decrease of LC3-I (p=0.041) in CV17q. (c) Individual tau band and total tau analyses 
normalized to actin show that 0.94uM has a decreasing effect on MAPT1 (p=0.001), and MAPT2 
(p=0.001) in CV17q cells. Graph, mean ± SEM, n=9 Treatment, n=72 Control.  
   
Nystatin 
 In four concentrations (A=11.6ug/mL, B=4.02ug/mL, C=1.39ug/mL, 
D=0.48ug/mL) (Figure 20) CV4a and CV17q showed no significant change in cell 
viability by resazurin in any concentration (Figure 20a). Within the CV4a cell line, 
Western blot showed a significant reduction in LC3-II/LC3-I ratio after treatment with 





to LC3-I or LC3-II (Figure 20b). Individual tau and total tau analyses normalized to 
actin (Figure 20c) exhibited an increase in MAPT1, MAPT2, and MAPT4 tau levels 
within the CV17q line at 4.02ug/mL when compared to control. 
 
Figure 20. Effects of treating cell lines with Nystatin in four concentrations. (a) Treatment with Nystatin 
show fold changes in cell viability by resazurin in CV4a (n=6 Control, n=3 Treatment) and CV17q (n=10 
Control, n=5 Treatment). There was no change in either CV4a or CV17q cell viability by any 
concentration. (b) Western blot results show LC3-I (left) and LC3-II (right) accumulation normalized to 
actin or ratio of LC3-II/LC3-I. There was a decrease in LC3-II/LC3-I ratio (p=0.001) in CV4a by 
0.48ug/ml. (c) Individual tau band and total tau analyses normalized to actin show an increase in MAPT1 




 In four concentrations (A=47.2uM, B=16.44uM, C=5.73uM, D=1.99uM) (Figure 
21) showed no change in cell viability by resazurin in CV4a. Effects of treating CV17q 
cells with FCCP (Figure 21) showed significant decrease in cell viability by resazurin for 







Figure 21. Effects of treating cell lines with FCCP in four concentrations. Treatment with FCCP show cell 
viability by resazurin in CV4a (n=6 Control, n=3 Treatment) and CV17q (n=10 Control, n=5 Treatment). 
There was only a decrease in CV17q cell viability by 47.2uM (p=0.004), and 5.73uM (p=0.001). 
 
PuAD  
 In four concentrations (A=1200nM, B=420nM, C=147nM, D=51.45nM) (Figure 
22) CV4a showed significant decrease in cell viability by resazurin for 1200nM and 
420nM (Figure 22a). Western blot showed a significant decrease in LC3-II/LC3-I ratio 
by 51.45nM (Figure 22b). Effects of treating CV17q cells with PuAD (Figure 22) 
showed significant decrease in cell viability by resazurin for 1200nM, 420nM, and 
147nM (Figure 22a). Individual tau and total tau analyses normalized to actin (Figure 
22c) exhibited an increase in MAPT4, MAPT5, and total tau within the CV4a line. Tau 
analysis also exhibited significant increases in MAPT1, MAPT2, MAPT3, MAPT4, 






Figure 22. Effects of treating cell lines with PuAD in four concentrations. (a) Treatment with PuAD shows 
fold changes in cell viability by resazurin in CV4a (n=6 Control, n=3 Treatment) and CV17q (n=10 
Control, n=5 Treatment). There was a decrease to cell viability in CV4a by 1200nM (p<0.001), and 420nM 
(p=0.005). There was a decrease to CV17q cell viability by 1200nM (p<0.001), 420nM (p<0.001), and 
147nM (p=0.029). (b) Western blot results show LC3-I (left) and LC3-II (right) accumulation normalized 
to actin or ratio of LC3-II/LC3-I. There was a decrease in LC3-II/LC3-I in CV4a by 420nM (p=0.031) and 
51.45nM (p=0.004). (c) Individual tau band and total tau analysis normalized to actin show an increase in 
MAPT4 at 420nM (p=0.004), MAPT5 at 420nM (p=0.001) and 51.45nM (p=0.004) within the CV4a cell 
line. Total tau levels seem to increase (p=0.015) by 420nM. Tau analysis indicates there were also increases 
in MAPT1 by 420nM (p<0.001) and 51.45nM (p=0.005), MAPT2 by 420nM (p<0.001) and 51.45nM 
(p=0.007), MAPT3 by 420nM only (p p<0.001), MAPT4 by 420nM (p<0.001) and 51.45nM (p=0.003), 
MAPT5 by 420nM (p=0.008), and total tau accumulation by 420nM (p<0.001) and 51.45nM (p=0.022) 
within the CV17q cell line. 
 
Vorinostat  
 In four concentrations (A=122uM, B=42.90uM, C=15.09uM, D=5.31uM (Figure 
23) CV4a showed significantly decreased cell viability by resazurin for all four 
concentrations in both CV4a and CV17q cell lines (Figure 23a). Western blot displayed 
a decrease in LC3-II/LC3-I ratio by 42.90uM and 5.31uM within the CV4a line. Within 
the CV17q line, there was no change in LC3-I or LC3-II after treatments (Figure 23b). 





increase in MAPT2, MAPT3, MAPT5, and total tau within CV4a. Tau analysis also 
exhibited an increase in MAPT1, MAPT2, MAPT3, MAPT4, MAPT5, and total tau 
within CV17q. 
 
Figure 23. Effects of treating cell lines with Vorinostat in four concentrations. (a) Treatment with 
Vorinostat show fold changes in cell viability by resazurin in CV4a (n=6 Control, n=3 Treatment) and 
CV17q (n=10 Control, n=5 Treatment). There was a decrease in cell viability by resazurin in both CV4a 
and CV17q cell viability by all concentrations (p<0.001). (b) Western blot results show LC3-I (left) and 
LC3-II (right) accumulation normalized to actin or ratio of LC3-II/LC3-I. Western blot showed a decrease 
in LC3-II/LC3-I ratio by 42.90uM and 5.31uM (p=0.012; p=0.006) within the CV4a line. Individual tau 
and total tau analyses normalized to actin exhibited an increase in MAPT2 by 42.90uM (p=0.012), MAPT3 
by 42.90uM (p=0.017), MAPT5 by 42.90uM (p=0.029), and total tau by 42.90uM (p=0.009) and 5.31uM 
(p=0.028) within CV4a. Tau analysis also exhibited an increase in MAPT1 by both concentrations 
(p<0.001; p<0.001), MAPT2 by both concentrations (p<0.001, p<0.001), MAPT3 by both concentrations 
(p<0.001, p<0.001), MAPT4 by both concentrations (p<0.001, p<0.001), MAPT5 by both concentrations 






Gene Expression Profiles in 2D vs 3-D Formats 
 Gene expression was analyzed by RT-PCR and results are displayed in Figure 24. 
Hierarchical clustering shows the similarities and differences based on the expression of 
each gene as increasing or decreasing when compared to CV4a control, Day 0 NPCs. 
Neural progenitor cells (Day 0) show low expression of neuronal, or oligodendrocytic 
genes in either CV4a or CV17q cell lines. Low levels of some astrocytic genes (Ptx3, 
Tcfcp2l1, Dmp1) can be seen being expressed in CV17q NPCs (Day 0). Adherent cells at 
day 28 show an increase in neuronal and astrocytic gene expression within both cell lines 
indicating mixed populations of cells and consistent with expected results. Neural sphere 
cultures at day 28 show some expression of only astrocytic genes within the CV4a line. 
Results indicate an upregulation of only neuronal genes, as well as increased MAPT 
expression in CV17q as compared to control NPCs at Day 0. One observation worth 
noting is that 4R MAPT was highly expressed and upregulated in all but one sample. 
 Because I was interested in tau protein expression, I looked specifically at MAPT 
protein variants. Leven’s test for equal variance found no significant differences in any 
group. Individual sample t-tests for equality of means determined MAPT3R in CV4a 3D 






Figure 24. Heat map displays gene expression analysis by hierarchical clustering and based on cell line 
(CV4a/CV17q) and cell type/format. (Left) NPC Day 0 cultures displayed low levels of all selected genes. 
(Middle) Adherent Day 28 cultures showed signs of containing all cell types based on gene expression. (Right) 
3-D Day 28 cultures showed evidence of variable cell types based on gene expression between cell lines and 
between replicates CV4a. White/grey/black gradient shows intensity of gene regulation as compared to CV4a 
NPC control. Each box has labeled intensity from 0-1. White boxes show downregulation, black boxes show 
upregulation, and grey shows no change in gene expression.   





Transiently Transfected Cells Display Signs of Successful Plasmid Integration. 
 Preliminary data in HEK293T cells (Figure 25) show high levels of GFP 
expression based on reporter gene promoters. HEK293t cells normally express EEF1A1 
gene and as expected EGFP expression was present after transient transfection of the 
EEF1A1-GFP plasmid cassette (Figure 25A). EGFP expression was also present after 
transfection with the EEF1A1-CRISPR plasmid (Figure 25B). Low levels of EGFP was 
present after transfection with the SYN1-GFP cassette (Figure 25C). Interestingly, 
HEK293t cells do not naturally express the SYN1 gene which may indicate abnormal 
gene expression, autofluorescence, or integration of EGFP via CRISPR. 
 Fluorescence microscopy reveals EGFP expression within specific cell types 
(Figure 26). Transfection rate/successful transfections could not be confirmed; however, 
specific cell types may be distinguished/distinct from each other based on morphology. 







Figure 25. EGFP expression in HEK293t cells based on reporter gene(s). All panels show varying degrees 
of EGFP expression. EEF1A1 reporter was used in panels A and B. SYN1 reporter was used in panel C. A) 
EGFP is highly expressed in HEK293t cells assumed to be caused by cell expression and induction by 
EEF1A1 promoter. B) HEK293t cells treated with EEF1A1-CRISPR cassette containing EGFP. C) 
HEK293t cells express low levels of EGFP after transfected with SYN1-CRISPR cassette. EGFP 
expression assumed to be due to CRISPR integration, though the SYN1 promoter should only be expressed 








Figure 26. Fluorescent microscopy reveals EGFP expression in iPSC derived neural cells. Cells were 
transfected with plasmid cassettes containing EGFP sequences induced by a cell type specific reporter 
promoter. (TOP) Brightfield microscopy (MIDDLE) GFP filter only (BOTTOM) Overlay of mCHERRY, 
GFP and brightfield images. After transfection, cells were subsequently differentiated by FGF withdrawal. 
A) EEF1A1, nine days differentiated. B) GFAP, nine days differentiated. C) CNP, nine days differentiated. 
D) SYN1, eighteen days differentiated. E) PRNP, twenty-eight days differentiated. 
 
EEF1A1 reporter designed to identify all cell types 
 Cells transfected with the EEF1A1 plasmid cassette express EGFP up to 24 hours 
after transfection. EGFP expression was monitored across a differentiation period of 28 
days. EGFP expression was observed as early as 24 hours after transfection up to 21 days 
(Figure 27). Morphology of cells are visually consistent with NPCs at day 0 and 
immature development of other cells at day 9. Morphology of astrocytes expressing 
EGFP was observed at around day 9 and up to day 21. Neuronal cell morphology was 









Figure 27. Neural cells after transfection with housekeeping EEF1A1-GFP plasmid cassette. Fluorescent 
microscopy reveals EGFP expression in iPSC derived neural cells. (TOP) Cells transfected with plasmid 
cassettes containing EGFP sequences induced by EEF1A1 reporter promoter. After transfection, cells were 
subsequently differentiated by FGF withdrawal. Lane 1 shows NPCs at day 0 of differentiation, 24 hours 
after transfection. Lane 2 shows nine days differentiated. Lane 3 shows 21 days differentiated. (BOTTOM) 
Enlarged image of differentiation day 21 displays cells expressing GFP. Red arrow shows possible 





GFAP reporter designed to identify astrocytes 
 Cells transfected with the GFAP plasmid cassette express EGFP as soon as 9 days 
after differentiation. EGFP expression was monitored across a differentiation period of 28 
days. EGFP expression was observed as early as 9 days after transfection up to 28 days 
(Figure 28). As expected, the morphology of cells is consistent with those of astrocytes 








Figure 28. Neural cells after transfection with astrocytic GFAP-GFP plasmid cassette. Fluorescent 
microscopy reveals EGFP expression in iPSC derived neural cells. (TOP) Cells transfected with plasmid 
cassettes containing EGFP sequences induced by GFAP reporter promoter. After transfection, cells were 
subsequently differentiated by FGF withdrawal. Lane 1 shows cells at day 2 of differentiation. Lane 2 
shows nine days differentiated. Lane 3 shows 21 days differentiated. Lane 4 shows 28 days differentiated. 
(BOTTOM) Enlarged image of differentiation day 9 exhibits cells expressing EGFP with a morphology 





CNP reporter designed to identify oligodendrocytes 
 Cells transfected with the CNP plasmid cassette express extremely low levels of 
EGFP. EGFP expression was monitored across a differentiation period of 28 days 
(Figure 29). Neither morphology of cells nor cell types containing EGFP can be 








Figure 29. Neural cells after transfection with oligodendrocytic CNP-GFP plasmid cassette. Fluorescent 
microscopy reveals extremely low levels of EGFP expression in iPSC derived neural cells. (TOP) Cells 
transfected with plasmid cassettes containing EGFP sequences induced by CNP reporter promoter. After 
transfection, cells were subsequently differentiated by FGF withdrawal. Lane 1 shows cells at day 2 of 
differentiation. Lane 2 shows nine days differentiated. Lane 3 shows 18 days differentiated. (BOTTOM) 





SYN1 reporter designed to identify neurons with synapses 
 Cells transfected with the SYN1 plasmid cassette express EGFP as soon as 9 days 
after differentiation. EGFP expression was monitored across a differentiation period of 28 
days. EGFP expression was observed as early as 9 days after transfection up to 18 days 
after differentiation (Figure 30). As expected, the morphology of cells that contain EGFP 
is visually consistent with those of neuronal cells. EGFP expression was observed at 
around day 9 and up to day 28 (not shown). 
 
Figure 30. Neural cells after transfection with Neuronal SYN1-GFP plasmid cassette. Fluorescent 
microscopy reveals relatively low levels of EGFP expression in iPSC derived neural cells. Cells transfected 
with plasmid cassettes containing EGFP sequences induced by SYN1 reporter promoter. After transfection, 
cells were subsequently differentiated by FGF withdrawal. Lane 1 shows cells at day 2 of differentiation. 
Lane 2 shows 9 days differentiated. Lane 3 shows 18 days differentiated. Enlarged images (indicated by red 





PRNP reporter designed to identify mature neurons 
 Cells transfected with the PRNP plasmid cassette express EGFP as soon as 9 days 
after differentiation. EGFP expression was monitored across a differentiation period of 34 
days. EGFP expression was observed as early as 9 days after transfection up to 34 days 
after differentiation (Figure 31). Cells expressing EGFP are assumed to be expressing the 
cell type specific gene PRNP. As expected, the morphology of cells is visually consistent 








Figure 31. Neural cells after transfection with neuronal PRNP-GFP plasmid cassette. Fluorescent 
microscopy reveals relatively high levels of EGFP expression in iPSC derived neural cells. Cells 
transfected with plasmid cassettes containing EGFP sequences induced by SYN1 reporter promoter. After 
transfection, cells were subsequently differentiated by FGF withdrawal. (TOP) Lane 1 shows cells at day 2 
of differentiation. Lane 2 shows 9 days differentiated. Lane 3 shows 28 days differentiated. Lane 4 shows 






DMEM only (control). 
 Cells transfected without a plasmid cassette displayed some nonspecific and 
unconfirmed EGFP expression. EGFP expression was monitored across a differentiation 
period of 28 days. Some EGFP expression was observed (Figure 32) but the morphology 
of cells may not be consistent with a specific cell type. It was not expected, but could 
there be some other mechanism of expressing EGFP? 
 
Figure 32. Neural cells after transfection with no plasmid cassette. Fluorescent microscopy reveals some 
EGFP expression in iPSC derived neural cells. After “transfection”, cells were subsequently differentiated 








Cell Culture and Differentiation 
 Human iPSCs and induced neural cells have allowed insight into the phenotypes 
of different neurodegenerative diseases (Israel et al. 2012). However, across tauopathies, 
it is unclear (i) which MAPT transcript variants and isoforms are predominant within 
disease-susceptible cells, (ii) how different tau isoforms are post-translationally modified 
and cleared from these susceptible cells, and (iii) whether there are differences in 
clearance and survival mechanisms between affected cell types (e.g. neurons vs. 
astrocytes). 
 Upon differentiation in neuronal media following FGF withdrawal, adhered 
monolayer cultures commonly produce cultures where restricted spatial factors establish 
connectome expansion (D'Aiuto et al. 2018). When NPCs are differentiated in either 
adhered or 3-D format, they are signaled to become one of the cell types of the brain. An 
important outcome of this project is that 3-D cultures did not necessarily differentiate to 
contain increased expression of astrocytic genes and/or oligodendrocytic genes (e.g. 
GFAP, CNP, etc.) in addition to neuronal gene expression; indicating restricted cell type 
differentiation. Monolayer cultures however, were expected to have a higher expression 
of neuronal genes with low expression of astrocytic/oligodendrocytic genes, due to the 
>90% neurons present in culture yet results indicate a constant expression within these 
cultures. Even though >90% of adherent cells become neurons, non-neuronal cell types 





al. 2009, Weber and Barros 2015). Though results did not support the hypothesis that 3-D 
neural cultures are more analogous to in vivo brain cells; the goal to produce mixed 
populations of neuronal and non-neuronal/glial cell types was achieved. 
 Due to difficulty in developing homogenous cell populations, the majority of 
recent studies attempt to recapitulate in vivo cell types using homogenized brain tissue 
(Tagliafierro et al. 2016). In this study, monolayer cultures representing homogenous cell 
populations were compared to 3-D cultures that represent brain homogenates. The 3-D 
were more prone to microbial contamination during collection, and an inadequate number 
of cells for differentiation was acquired. These factors also affected the quality of 
obtainable RNA. In addition to clearing samples of genomic DNA and protein 
contamination, using a more robust RNA extraction method may achieve increased 
greater quantities of purified RNA samples. It is critical that precautions are taken when 
collecting cells in order to minimize contact with contaminated surfaces and laboratory 
equipment. The total number of initial cells should be increased in 3-D cultures to ensure 
a sufficient quantity of cells and subsequently RNA extracts. Geometry and composition 
have been seen to influence genes’ expression, and some genes promoting cell 
proliferation are repressed in 3-D culture (Edmondson et al. 2014). The original seeding 
density was determined by previous lab protocols based on proliferation rates of adherent 
cultures therefore proliferation, growth and development of 3-D cultures should be 







 Preliminary studies on the amplification of the 17q chromosome have indicated 
an increase in MAPT gene products resulting from a third copy of the MAPT gene (Dizon 
2016). This work has established an increased expression of tau transcripts in iPSC lines 
as a possible diseased neural model. Due to copy number variation on chromosome 17, 
cell cultures of mixed neuronal/glia or purified neurons were characterized by RT-qPCR 
for MAPT 3R and 4R tau protein expression indicative of mixed tauopathies such as 
chronic traumatic encephalopathy, and Frontotemporal dementia and Parkinsonism liked 
to Chromosome 17; including evaluation of how total tau levels are influenced by this 
third copy of the MAPT gene. Western blot was used to measure protein levels in 
wildtype CV4a vs several experimental lines including CV17q. Tau levels were 
determined to be significantly higher in experimental cells, signifying either an increase 
in MAPT expression or an impairment of turnover processes. The Western blot was 
incubated with isoform specific tau antibodies and band sizes were found to be consistent 
with and assumed 3R2N and 3R1N tau isoforms. Based on the MSD pT231/total tau 
assay, it is likely that altered turnover is driving tau accumulation (Lotfy 2016). Based on 
these results, it appears that mixed populations of cells tend to accumulate more tau 
protein when compared to purified neuronal cultures. This may indicate that excess tau is 
produced, or accumulated, in non-neuronal or supportive glial cells. 
Immunocytochemistry on mixed vs purified cultures might determine whether or not 





environments. When cell viability is decreased, any subsequent reports of change at the 
protein level may be caused by a decrease in living cells within that culture or possible 
toxicity in the treatment(s). As an indicator of autophagosome formation, any observed 
drug effects on the LC3 protein accumulation is dependent on LC3-I conversion into 
LC3-II. When LC3-II protein levels increase, the cause may be that the drug is either an 
inhibitor of the ubiquitin proteasome system and activation of autophagy has been 
achieved, or that the autophagy pathway has been inhibited and the cells do not clear 
autophagosomes. 
Autophagy and Ubiquitin Proteasome Degradative Pathways 
 Misfolded tau protein is degraded primarily by the autophagy pathway and may 
be alternatively degraded via ubiquitin proteasome (Lee et al. 2013). Drug treatment and 
molecular MAPT targeting may analyze tau degradation via autophagy and/or ubiquitin 
binding. In this study, a library of activators and inhibitors of autophagy and ubiquitin 
binding were screened (Table 1) and tau accumulation was directionally quantified by 
Western blot. My hypothesis was that activation of autophagy will stimulate the 
degradation of total tau protein whereas inhibition of the autophagy pathway results in 
accumulation of misfolded and/or native tau causing accelerated cell death in each cell 
type. It is likely that the autophagy and UPS pathways degrade distinct/different tau 
proteins, and so it is important to identify which tau proteins are accumulating and 






 Cell viability results indicate that an observed decrease at a treatment 
concentration that produced a significant change in cell metabolism by resazurin, 
regardless of cell line, may or may not implicate an effect of the drug. While there were 
different correlations between concentration and treatment (Figure 11; Figure 12) 
analysis of concentrations B and D were selected to keep consistency between treatments 
(Table 2; Table 5). Concentrations B and D were chosen because in most cases, 
concentration B showed there was at least some reduction in cell viability after treatment 
while concentration D frequently displayed the least amount of cell viability change. 
SCD1 and FCCP were excluded completely from protein analysis in the interest of time.  
 Inhibiting mTOR mimics starvation of the cell which in turn stimulates autophagy 
and signals homeostatic processes within the cell (Altomare and Khaled 2012). It was 
expected that treating cells with Rapamycin would either reduce protein levels by 
inducing autophagy or that protein levels would remain the same due to constitutive 
autophagy. The decrease as seen in LC3-II/LC3-I ratio by rapamycin was not consistent 
with other results. Rapamycin at 20uM increases LC3-II production indicating enhanced 
autophagosome formation (Lin et al. 2018). In the present study, we see a reduction of 
LC3-II/LC3-I by Rapamycin at 0.20uM within CV4a cells which could indicate normal 
autophagosome clearance. No change in protein accumulation could also indicate normal 






 Similar to the effects of Rapamycin, I expected that treating cells with Torin1 
would reduce protein levels through autophagy induction or that protein levels would 
remain the same due to constitutive autophagy. Torin1 aggravates cytotoxicity (Huang et 
al. 2017), suggesting that mTOR inhibition may not be able to alleviate neurotoxicity. In 
the present study, the decrease seen in cell viability at concentrations higher than 0.08uM 
could be due to toxicity. As with the presence of LC3-II protein being an indicator of 
autophagosome formation, the reduction of LC3-II/LC3-I by Torin1 could indicate 
autophagosome clearance.  
 Spautin1, a small molecule inhibitor of ubiquitin-specific peptidase 10 and 13 
affects autophagy by LC3-II inhibition (Liu et al. 2011). An observed decrease of cell 
viability by 14.3uM and 4.85uM in both cell lines are consistent with decreased cell 
survival (Schott et al. 2018) though this study showed no significant changes in LC3 
accumulation.  
 It was hypothesized that inhibition of autophagy with BafA1 would render 
derived neural cells incapable of autophagosome formation which may be what so 
negatively affected cell viability in all concentrations. Increase of LC3-II/LC3-I in both 
CV4a and CV17q cell lines by 73.44nM support this hypothesis indicating impaired 
autophagy at this concentration. The decrease of MAPT1, MAPT2, MAPT3, MAPT5, 
and total tau observed in CV17q cells at 8.49nM could indicate an alternative mechanism 
by which the tau protein is cleared from the cells and CV17q may be more sensitive to 
tau degradation after treatment with BafA1. Another possibility could be because CV17q 





 Inhibition with chloroquine should increase tau protein, but findings suggest an 
autophagy independent, ubiquitin proteasome pathway and separate mechanism for tau 
degradation. Inhibition of lysosomal acidification with chloroquine disrupts autophagy 
function (Kimura et al. 2013). This may be the source of LC3-II/LC3-I increase in CV4a 
cells. The MAPT1, MAPT2, and MAPT3 decrease of tau proteins observed in CV17q 
cells at 8.77ug/mL indicate an alternative mechanism by which these tau isoforms (but 
not others) are cleared from the cells. CV17q may be more sensitive to tau degradation 
after treatment with Chloroquine, or because CV17q accumulates more tau protein it is 
much easier to see. The number of cells and/or total protein required to evaluate this must 
be increased in the CV4a cell line.  
 After treatment with MG-132, an increase of LC3-II within the CV4a cell line at 
7.69uM and decrease by 0.91uM implicate higher concentrations of MG-132 in cell 
death/apoptosis or that higher concentrations reduce the degradation of ubiquitin 
conjugated proteins by which LC3-II accumulation occurs. The increase of MAPT4 in 
CV4a could be the effect of drug treatment, or the source of decreased cell viability. 
Interestingly, in CV17q, the decrease of MAPT1 by 0.91uM and increase of MAPT2 and 
MAPT4 by 7.69uM may suggest a separate mechanism by which MAPT1 is cleared, but 
not MAPT2 or MAPT4. This may also suggest cell death due to protein clearance failure 
at higher concentrations.  
 Reduction of LC3-II/LC3-I by Nystatin at 0.48ug/mL within CV4a could indicate 
normal autophagy function but there was a significant increase in only CV17q MAPT 





accumulation of tau as compared to CV4a. CV17q may be more sensitive to drug 
treatments, but in order to evaluate this outcome, the number of cells and/or total protein 
must be increased in the CV4a cell line.  
 Cell viability decreased with PuAD treatment at higher concentrations (1200nM; 
420nM) in both cell lines. This is not consistent where viability of iPSC-derived neurons 
showed little change after 72hr treatment with PuAD in concentrations ranging from 0-
100 uM (Inda et al. 2020). Concentrations of PuAD in the present study were 
significantly higher and could be the cause of increased cell death. Inhibition of HSP90 
affects the ubiquitin proteasome system where a reduction in LC3-II/LC3-I may indicate 
autophagy activation. The increase in MAPT4, MAPT5, and total tau within CV4a and 
additionally, increase of all tau protein by 420nM and an increase of MAPT1, MAPT2, 
MAPT4, and total tau by 51.45nM in CV17q could be the result of normal autophagy 
function with no mechanism for degradation of these MAPT proteins (Inda et al. 2020).  
 Treatment with Vorinostat may not affect autophagy function but all tau 
measurements indicate increased tau accumulation at least in the CV17q cell line. CV4a 
follows the trend of increasing tau protein, however this could be due to Vorinostat 
having less of an effect on healthy control cells. Loaded Western blots with Vorinostat 
treated samples may be skewed due to an obstruction caused by the tau protein ladder 
with bleeding signal through adjacent wells. Data cannot be confirmed here and further 





Profile Analysis of Gene Expression Between 2D vs 3-D, in Control vs “Diseased” Cell 
Lines 
 Comparisons were made between CV4a and CV17q cell lines where identification 
of cell type (neurons, astrocytes, and oligodendrocytes) specific genes may yet elucidate 
gene expression profiles for these cell lines. Based on the bioinformatics technique 
proposed in Cahoy et al. (2008) the selected genes (Table S1) were expected to be 
expressed in neurons: (1)Neurod6, (2)Vip, (3)Gabra5, (4)Satb2, (5)Sla, (6)Odz2, (7)Crh, 
(8)Syt1, (9)Dlx1, (10)Pgm2l1 (11)TUBA1A; (12)SYN1; Astrocytes: (1)Tnc, (2)Pla2g7, 
(3)Emp1, (4)Tgif2, (5)Ptx3, (6)Agxt2l1, (7)Tcfcp2l1, (8)Dmp1, (9)Sult1a1, (10)Gjb6; 
Oligodendrocytes: (1)Mobp, (2)Cpm, (3)Adamts4, (4)Enpp6, (5)Mog, (6)Ugt8a; and 
constitutive housekeeping genes: (1)GAPDH, (2)Tbp, (3)RPL27, (4) EEF1A1.  
 Differences in gene expression that are described in the results (Figure 24) are 
seemingly contradictory to my hypothesis that 3-D neural spheres are comparable as an 
in vivo model however, non-adhered 3-D cultures have proven difficult to manage. Any 
disturbance to the cultures such as weekly media changes caused a loss of some cells or 
entire cultures. The fragility of the cultures requires a skillfulness acquired by proper 
training and experience (lab experience) by which one could efficiently reproduce the 
experiment with improved results. 
 A major component of this project was to specifically monitor levels of total, 3R, 
and 4R tau protein within cell cultures. Because tau is expressed in most human central 





was to elucidate different isoform expression (3R and 4R tau) compared to total tau to 
determine if cells generate higher expression of one isoform over the other. Results 
established that only 3R tau was significantly increased in my CV17q 3-D model when 
compared to CV4a (3-D) neural spheres. These results could be due to the amplification 
region included in the CV17q cell line.  
Integration of Cell Type Specific EGFP Induced Plasmid Cassettes and Fluorescent 
Microscopy 
 Cell type specific fluorescent reporters at the AAVS1 safe harbor locus have been 
developed and stably integrated in tauopathy-like and healthy control lines. The 
construction of fluorescent reporter plasmid tools includes cell type specific promoters 
and EGFP to distinguish individual cells within each cell population. PRNP, SYN1, 
GFAP, CNP, and EEF1A1 plasmids have been constructed and gel electrophoresis has 
confirmed the presence of the correct plasmid amplification sizes (Figure 5). The goal at 
this stage was to identify the key cell populations that are negatively affected by 
tauopathies (oligodendrocytes, astrocytes, neurons) and to compare the results of these 
reporter studies to our gene expression profiles at various stages of differentiation. EGFP 
labeled cells allowed for differences in gene expression to be visualized by fluorescence 
microscopy and immunofluorescence. As cells differentiate, cell signaling and gene 
expression determine cell fate. Although there are many cell type specific genes 
expressed at any developmental stage, any gene may be activated at any point across 





expression, but if at any point a cell expresses a reporter gene within its relative 
condition, that promoter then influences the expression of EGFP. A neural progenitor cell 
may become a neuron, but in order to become a neuron, any number of genes in any 
combination could be regulated and/or expressed during the differentiation process until 
that cell’s fate is determined. Problems/pitfalls of this aim could include unpredicted 





SUMMARY AND FUTURE DIRECTION 
 Deaths associated with tauopathies are still considered "incurable"; therefore, 
construction of novel preventive technology must be fully explored. A large-scale 
production of distinct cell types affected by a specific disease would be useful for disease 
modeling, drug discovery, and autologous cell replacement therapies where the 
possibility of prevention should be examined as an alternative to the direct assault on 
proteins through medicating.   
 Mapping distinct cell signaling pathways and tracking their reactions over time 
during specific stages of a life cycle via gene expression and protein markers are a rising 
trend in the field of biology and bioinformatics (Zhou et al. 2016). Gene 
function/expression in individual cells and/or whole cell lineages may be regulated with 
the potential to survey one or multiple cell signaling pathways at a time. The 
configuration and development of experimental cell lines based on biochemical signaling 
in the presence of certain transcription factors would distinguish gene function within 
individual cell types. Rather than relying on the continued use of medications that have 
demonstrated minor efficacy for treating tauopathies, future direction will target upstream 
signaling and post-translational modifications for novel treatment and prevention 
strategies. Enhanced cell culture techniques may have the potential of improving the data 
from the neural models studied in this project. It remains unconvincing to me that the 
results obtained from the 3-D neural sphere cultures are accurate depictions of their gene 





media changes, re-adherence of 3-D neural spheres might reduce the probability of 
damage to the scaffolding structures and loss of sample, thus increasing the likelihood of 
improved neural modeling (Figure. 33). 
 
Figure 33. Bright field micrographs of 2D monolayer (left) and 3-D neural spheres (right). Cells displayed 
here were cultured from CV17q iPSC derived neural progenitor cells and further differentiated. (Left) 
Bright field microscopy shows the monolayer cell cultures, traditionally used in neural developmental 
research. (Right) Bright field microscopy showing different growth stages of differentiated neural spheres. 
Axons and dendrites can be more easily distinguished in the 3-D cultures as well as obvious connections 
that are being made between cells. 
 
 Rather than relying on the continued use of medications that have demonstrated 
minor efficacy for treating tauopathies, future direction will target upstream signaling and 
post-translational modifications for novel treatment and prevention strategies. A stably 
integrated cell type specific fluorescent reporter at the AAVS1 safe harbor locus in 
tauopathy-like and healthy control lines has been developed. In future projects, these 
tools can be coupled with a CRISPR system to systematically dissect cell type specific 
phenotypes in high resolution using modern genetic tools. It would be helpful to use 
CRISPRs in order to: (1) insert these tools at a known locus in the human genome 
without interference with other genes; (2) control for copy number and expression level; 
and (3) avoid experimental heterogeneity associated with random viral integration or 





 Whether native and/or misfolded tau is cleared and recycled by specific 
degradative pathways must still be investigated. Autophagosome formation genes, as well 
as ubiquitin cargo recruitment genes can be targeted by sgRNA sequences to initiate gene 
interference and/or activation by the plasmids constructed in this experiment with the 
iCRISPRi/dCas9 system (Figure. 2; Figure. 5). The regulation of autophagic 
mechanisms by enhanced drug screening and/or gene expression could identify and 
confirm autophagosome and/or ubiquitin binding inhibition. iCRISPRi constructs could 
be integrated into the AAVS1 safe harbor locus of these isogenic human iPSC lines and 
knockdown by cell specific promotor control, targeting autophagosome formation genes 
and ubiquitylated cargo recruitment genes could confirm mechanisms in drug induced 
intervention. This will also provide a different type of (drug) treatment as a possible 
prevention rather than the present search for a cure. Neural development and survival are 
dependent on constitutive autophagy, gene regulation and cell signaling; and the 
dysregulation of these functions leads to neurodegeneration. Understanding these 
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